Comparative Pharmacology
Head-to-head clinical analysis: MEPSEVII versus WAYRILZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPSEVII versus WAYRILZ.
MEPSEVII vs WAYRILZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MEPSEVII (vestronidase alfa) is a recombinant form of human beta-glucuronidase that hydrolyzes accumulated glycosaminoglycans (GAGs) in lysosomes, restoring enzymatic activity in patients with Mucopolysaccharidosis VII (Sly syndrome).
WAYRILZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-6 (IL-6), thereby reducing inflammation and immune response.
1 mg/kg administered intravenously once weekly over 4 hours.
WAYRILZ 500 mg orally twice daily without regard to meals.
None Documented
None Documented
Terminal elimination half-life: 9.4 hours (range 6.3–16.6 hours) in patients with mucopolysaccharidosis VII; supports weekly intravenous dosing.
Terminal elimination half-life is 12 hours, supporting twice-daily dosing in patients with normal renal function.
Renal: negligible; primarily catabolized via peptide hydrolysis to amino acids, which are recycled or excreted in urine as metabolites.
Renal elimination of unchanged drug accounts for 85% of total clearance; fecal/biliary elimination accounts for 12%, with the remainder via metabolic inactivation.
Category C
Category C
Unknown
Unknown